论文部分内容阅读
目的:分析经肝动脉灌注介入治疗对行肝癌微波消融术患者血清胸苷激酶1(TK1)及趋化因子CXC配体13(CXCL13)水平的影响。方法:以本院2014年12月至2019年1月期间诊治的行肝癌微波消融术患者为研究对象进行前瞻性研究。140例患者采用随机数字表法分为两组：对照组(n n＝70)患者行肝癌微波消融术治疗，观察组(n n＝70)患者行肝癌微波消融术前行经肝动脉灌注化疗，分析两组患者的临床效果及治疗前后血清TK1及CXCL13水平的变化情况。n 结果:观察组患者的总有效率明显高于对照组患者(92.9% vs 81.4%，n P<0.05)，两组患者经治疗后谷草转氨酶[观察组(40.4±6.69)U/L，对照组(52.3±8.33)U/L]、谷丙转氨酶[观察组(40.1±6.96)U/L，对照组(49.9±6.97)U/L]及总胆红素[观察组(24.5±3.96)mmol/L，对照组(35.2±6.31)mmol/L]水平均明显降低(n P<0.05)；治疗后患者血清中TK1[观察组(10.5±3.69)μg/L，对照组(15.4±4.28)μg/L]及存活素[Survivin，观察组(12.6±2.54)μg/L，对照组(19.2±4.15)μg/L]水平明显降低(n P<0.05)；而染色体10上磷酸同源性张力缺失基因[PTEN，观察组(46.9±5.33)μg/L，对照组(30.2±4.77)μg/L]水平明显升高(n P<0.05)，CXCL13[观察组(20.3±4.58)μg/L，对照组(32.5±5.11)μg/L]、CXCL16[观察组(23.3±4.77)μg/L，对照组(31.2±5.24)μg/L]及CXC趋化因子受体5(CXCR5)[观察组(10.1±2.77)μg/L，对照组(14.6±2.96)μg/L]水平明显降低(n P<0.05)，且观察组患者经治疗后上述指标的变化程度较对照组患者的变化更明显(n P<0.05)。n 结论:经肝动脉灌注介入治疗对行肝癌微波消融术有效率更高，且能有效降低患者血清TK1及CXCL13水平。“,”Objective:To investigate the effect of interventional therapy via hepatic artery on serum thymidine kinase 1 (TK1) and chemokine ligand 13 (CXCL13) levels in patients undergoing microwave ablation of hepatocellular carcinoma.Methods:A prospective study was conducted in patients with hepatocellular carcinoma treated by microwave ablation in our hospital from December 2014 to January 2019. 140 patients were divided into two groups according to random number method. The control group (n n=70) received microwave ablation for hepatocellular carcinoma. The observation group (n n=70) received hepatic artery perfusion chemotherapy before microwave ablation for hepatocellular carcinoma. The clinical effects of the two groups and the changes of serum TK1 and CXCL13 levels before and after treatment were analyzed.n Results:The total effective rate in the observation group was significantly higher than that in the control group (92.9% vs 81.4%; χ n 2=2.854, n P<0.05). The levels of aspartate aminotransferase (AST) [(40.4±6.69)U/L vs (52.3±8.33)U/L], alanine aminotransferase (ALT) [(40.1±6.96)U/L vs (49.9±6.97)U/L] and total bilirubin (TBIL) [(24.5±3.96)mmol/L vs (35.2±6.31)mmol/L] in the two groups were significantly decreased after treatment (n P<0.05). After treatment, the levels of TK1 [(10.5±3.69)μg/L vs (15.4±4.28)μg/L] and Survivin [(12.6±2.54)μg/L vs (19.2±4.15)μg/L] in the serum were significantly decreased (n P<0.05), while the levels of gene of phosphate and tension homology deleted on chromsome ten (PTEN) [(46.9±5.33)μg/L vs (30.2±4.77)μg/L] were significantly increased (n P<0.05); the levels of CXCL13 [(20.3±4.58)μg/L vs (32.5±5.11)μg/L], CXCL16 [(23.3±4.77)μg/L vs (31.2±5.24)μg/L] and CXC chemokine receptor 5 (CXCR5) [(10.1±2.77)μg/L vs (14.6±2.96)μg/L] were significantly decreased (n P<0.05). After treatment, the changes of the above indexes in the observation group were more obvious than those in the control group (n P<0.05).n Conclusions:Interventional therapy via hepatic artery perfusion is more effective for microwave ablation of hepatocellular carcinoma, and can effectively reduce the serum TK1 and CXCL13 levels in patients with hepatocellular carcinoma.